These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10436548)

  • 1. [Quinolones: historic review].
    Rothlin RP
    Medicina (B Aires); 1999; 59 Suppl 1():3-7. PubMed ID: 10436548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolone activity against anaerobes.
    Appelbaum PC
    Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolone activity against anaerobes: microbiological aspects.
    Appelbaum PC
    Drugs; 1995; 49 Suppl 2():76-80. PubMed ID: 8549420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of quinolones on intestinal ecology.
    Edlund C; Nord CE
    Drugs; 1999; 58 Suppl 2():65-70. PubMed ID: 10553709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolones: clinical use and formulary considerations.
    Cunha BA
    Adv Ther; 1998; 15(5):277-87. PubMed ID: 10345149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and residue studies of quinolone compounds and olaquindox in poultry.
    Anadón A; Martinez-Larrañaga MR; Diaz MJ; Velez C; Bringas P
    Ann Rech Vet; 1990; 21 Suppl 1():137S-144S. PubMed ID: 2080842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New classification and update on the quinolone antibiotics.
    King DE; Malone R; Lilley SH
    Am Fam Physician; 2000 May; 61(9):2741-8. PubMed ID: 10821154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of quinolones: newer aspects.
    Wolfson JS; Hooper DC
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):267-74. PubMed ID: 1864287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics and tissue penetration of the fluoroquinolones.
    Bergeron MG
    Clin Invest Med; 1989 Feb; 12(1):20-7. PubMed ID: 2920479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic focus. The fluoroquinolones.
    James DG
    Br J Clin Pract; 1989 Feb; 43(2):66-7. PubMed ID: 2679837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.
    Hayasaki Y; Itoh S; Kato M; Furuhama K
    Toxicol In Vitro; 2006 Apr; 20(3):342-6. PubMed ID: 16171969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the quinolones.
    Andersson MI; MacGowan AP
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():1-11. PubMed ID: 12702698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
    Neuman M
    Clin Pharmacokinet; 1988 Feb; 14(2):96-121. PubMed ID: 3282749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded activity and utility of the new fluoroquinolones: a review.
    Blondeau JM
    Clin Ther; 1999 Jan; 21(1):3-40; discussion 1-2. PubMed ID: 10090423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
    Goldstein EJ
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fluoroquinolone antibacterials: past, present and future perspectives.
    Appelbaum PC; Hunter PA
    Int J Antimicrob Agents; 2000 Sep; 16(1):5-15. PubMed ID: 11185413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.